Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
19/08/2025
Xiaomi Group CEO Lu Weibing: Plans to enter the European electric vehicle market in 2027.
Latest
2 m ago
In pre-market trading on Tuesday, U.S. stocks, Xiaoying Technology rose by 8.8%. The company's second quarter revenue increased by 65.6% year-on-year, with the total amount of loans facilitated and disbursed reaching a record 38.99 billion yuan, an increase of 71.4% year-on-year; the number of active borrowers increased by 73.7% year-on-year, reaching 2.85 million.
2 m ago
Zhongguang Lightning Protection: The company's customized and developed high-performance, ultra-large current flow T1 AC SPD is currently in the sample stage.
2 m ago
Due to lower-than-expected mid-term trial data for Viking Therapeutics' (VKTX.US) experimental oral weight loss drug, the stock plummeted nearly 34% in pre-market trading on Tuesday. Viking stated in a release that their oral GLP-1R/GIPR dual agonist VK2735 can help patients lose up to 12.2% of their weight. However, about 28% of patients dropped out of the trial in just three months, diminishing confidence in the drug's ability to compete with drugs from Eli Lilly (LLY.US) and Novo Nordisk (NVO.US). Mizuho Securities analyst Jared Holz noted, "It's worth noting the high dropout rate of patients within the 13-week period."
2 m ago
Viking's pre-market plunge, mid-term trial results of oral weight-loss drug VK2735 fall short of expectations.
3 m ago
Before the US stock market opened on Tuesday, New Oriental fell 1.7%. The company denied CEO's involvement in related-party transactions on Tuesday, causing Dongfangzhenxuan's Hong Kong stocks to plunge today.
See all latest
